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ABSTRACT
Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a
reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer’s
disease). Recent studies showed that treatment with donepezil reduced production of inﬂammat-
ory cytokines in PBMCs (peripheral blood mononuclear cells). It was also reported that muscle-
derived inﬂammatory cytokines play a critical role in neovascularization in a hindlimb ischaemia
model. We sought to determine whether donepezil affects angiogenesis. A hindlimb
ischaemia model was created by unilateral femoral artery ligation. Blood ﬂow recovery examined
by laser Doppler perfusion imaging and capillary density by immunohistochemical staining of
CD31-positive cells in the ischaemic hindlimb were signiﬁcantly decreased in donepezil- and
physostigmine-treatedmicecomparedwithcontrolmiceafter2 weeks.Donepezilreducedexpres-
sion of IL (interleukin)-1β and VEGF (vascular endothelial growth factor) in the ischaemic hindlimb.
Intramuscular injections of IL-1β to the ischaemic hindlimb reversed the donepezil-induced VEGF
down-regulation and the anti-angiogenic effect. Hypoxia induced IL-1β expression in C2C12
myoblast cells, which was inhibited by pre-incubation with ACh (acetylcholine) or LY294002,
a PI3K (phosphoinositide 3-kinase) inhibitor. Donepezil inhibited phosphorylation of Akt [also
known as PKB (protein kinase B)], a downstream kinase of PI3K, in the ischaemic hindlimb.
These ﬁndings suggest that cholinergic stimulation by acetylcholinesterase inhibitors suppresses
angiogenesis through inhibition of PI3K-mediated IL-1β induction, which is followed by reduction
of VEGF expression. Acetylcholinesterase inhibitor may be a novel anti-angiogenic therapy.
INTRODUCTION
Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-
dimethoxy-2,3-dihydroinden-1-one} is a speciﬁc and
reversible acetylcholinesterase inhibitor that increases
bioavailability of ACh (acetylcholine), a neurotrans-
mitter both in the CNS (central nervous system) and
PNS (peripheral nervous system). Donepezil is used for
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treatment of patients with AD and known to improve
cognitive function [1]. Treatment of the patients with AD
with donepezil is associated with reduction in the serum
cytokine level and cytokine production from PBMCs
(peripheral blood mononuclear cells) [2], suggesting a
possible anti-inﬂammatory effect of donepezil.
Recent studies suggest that ACh, a neurotransmitter
of the vagus nerve, has an anti-inﬂammatory effect
[3]. VNS (vagus nerve stimulation) attenuated TNFα
(tumour necrosis factor α) secretion from macrophages
and hypotension induced by LPS (lipopolysaccharide)
[4].AChinhibitsactivationofNF-κB(nuclearfactorκB)
[5]andinducessuppressorofcytokinesignal3expression
in macrophages [6], resulting in the attenuation of
inﬂammatory responses. Therefore it is possible that
acetylcholinesterase inhibitor attenuates inﬂammation
through activation of this so-called cholinergic anti-
inﬂammatory pathway.
Inﬂammationisaregulatedresponsetoharmfulstimuli
such as infection and ischaemic/hypoxic injury [7] and
also plays a pivotal role in neovascularization [8]. The
enhancement of angiogenesis by inﬂammation is partly
explained by production of various angiogenic growth
factors such as VEGF (vascular endothelial growth
factor), bFGF (basic ﬁbroblast growth factor), PDGF
(platelet-derived growth factor) and MCP (monocyte
chemoattractant protein)-1 from the leucocytes inﬁlt-
ratedintotheischaemictissue[9].Itwasalsoreportedthat
IL (interleukin)-1β secreted from regenerating muscle
after hindlimb ischaemia is critical for the enhanced
neovascularization by implantation of PBMCs [10].
These studies prompted us to study the effect of
cholinergic stimulation by donepezil on angiogenesis in
a mouse model of hindlimb ischaemia. In the present
study, we showed that pharmacological stimulation of
cholinergic system by acetylcholinesterase inhibitors
suppressed angiogenesis through inhibition of IL-1β
induction.
MATERIALS AND METHODS
Materials
DMEM (Dulbecco’s modiﬁed Eagle’s medium) was pur-
chased from Gibco BRL. FBS (fetal bovine serum) was
from JRH Biosciences. Donepezil was purchased from
Tronto Research Chemicals. ACh, physostigmine, heat-
inactivated horse serum and BSA were purchased from
Sigma. Mouse recombinant IL-1β was purchased
from PeproTec. An anti-CD31 (PECAM1) antibody was
purchased from Santa Cruz Biotechnology. Antibodies
against ERK (extracellular-signal-regulated kinase), p38
MAPK (mitogen-activated protein kinase), JNK (c-Jun
N-terminal kinase) and Akt and their phosphorylated
(p) forms were obtained from Cell Signaling Technology.
HRP (horseradish peroxidase)-conjugated secondary
antibodies (anti-rabbit or anti-mouse IgG) were
purchased from Vector Laboratories. SB203580 was a
gift from GalxoSmithKline. PD98059 was purchased
from BIOMOL Research Laboratories. LY294002 and
SP600125 were purchased from Sigma. Other chemical
reagents were purchased from Wako Pure Chemicals
unless mentioned speciﬁcally.
Cell culture
C2C12 (mouse myoblast cell) cells were obtained from
the RIKEN BioResource Center. C2C12 cells were
maintained in low-glucose DMEM supplemented with
10% FBS (growth medium) at 37◦C in a humidiﬁed
atmosphere of 95% air/5% CO2. C2C12 cells were
grown to conﬂuence, cultured in DMEM with 5% horse
serum (differentiation medium) for additional 2 days and
used in the experiment.
qRT–PCR (quantitative reverse
transcription–PCR)
Total RNA was prepared by an acid guanidinium/
phenol/chloroform extraction method with ISOGEN
(Nippon Gene) according to the manufacturer’s in-
structions. Then the total RNA (0.4 μg) was reverse-
transcribed using moloney murine leukaemia virus
RT (ReverTra Ace-α kit; Toyobo). The expression of
mRNA was determined using SYBR-green (Toyobo)
RT–PCR method and normalized to mouse β-actin
expression. Primer sequences used in the present study
are shown in Supplementary Table S1 (at http://www.
clinsci.org/cs/123/cs1230241add.htm). ABI Prism 7500
Sequence Detection System (Applied Biosystems) was
used.
Animal experiment
All procedures were approved by the institutional
animal use and care committee and were conducted in
conformity with institutional guidelines and Guide for
Care and Use of Laboratory Animals (NIH Publication
No. 85–23, revised 1996). Nine-week-old C57BL/6 mice
werepurchasedfromKyudo.Micewereanaesthetizedby
a bolus intraperitoneal injection of ketamine (90 mg/kg
of body weight) and xylazine (4 mg/kg of body weight),
which allowed approximately 60 min of anaesthesia for
creation of hindlimb ischaemia and implantation of
osmotic minipumps. The adequacy of anaesthesia was
monitored by conﬁrming the absence of the movement
of the mice during the surgical procedure. To produce
hindlimb ischaemia, the proximal portion of the left
femoral artery including the deep branches was ligated,
followedbyligationofdistalportionofsaphenousartery.
Thearteryandallsidebranchesbetweentwoligationsites
were excised completely. Then the mice were allotted
to the donepezil group, the physostigmine group or
the control group in a random manner. Donepezil was
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suspended in water, and administered ad libitum.T h e
estimateddoseoforallyingesteddonepezilwas10 mg/kg
of body weight per day. Some of the donepezil-treated
mice were given an intramuscular injection of 0.5 ng of
mouse recombinant IL-1β to the ischaemic limb on days
3, 5 and 7 after the operation.
Physostigmine (2 mg/kg of body weight per day)
was administered via an osmotic minipump (Alzet).
Physostigmine [11] and donepezil [12] at doses
used in this study were reported to inhibit brain
acetylcholinesterase activity by 62 and 45% respectively.
Nicotine (approximately 12 mg/kg of body weight
per day) and bethanechol (approximately 20 mg/kg of
body weight per day) were orally administered. The
doses of nicotine and bethanechol were determined
based on previous studies [13,14]. BP (blood pressure)
and HR (heart rate) were measured using tail-cuff
method (UR-5000; Ueda). Hindlimb blood perfusion
was measured by a laser Doppler perfusion imaging
system (Moor Instruments LDI). Before imaging, mice
were placed on a heating plate at 37◦C to minimize the
inﬂuence of temperature. After 2 weeks, mice were killed
with an overdose of pentobarbital anaesthesia and the
gastrocnemial muscle was quickly removed.
Immunohistochemistry
The gastrocnemial muscle was harvested and ﬁxed
overnightin10%buffered-formaldehyde.Afterﬁxation,
the tissue was embedded in parafﬁn and serial cross-
sections of the muscle were used for immunohisto-
chemical analysis. Parafﬁn sections were deparafﬁnized
and then subjected to heat-induced antigen retrieval
for 15 min at 90◦C in citrate buffer (pH 6.0). Blocking
of the section was performed with 2% BSA for
1 h at room temperature (25◦C). The sections were
incubated with a rat monoclonal anti-CD31 (PECAM1)
antibody diluted 1:200 in blocking solution at 4◦C,
which was followed by incubation with Alexa Fluor®
555-conjugated rabbit anti-(rat IgG) diluted 1:1000 in
blocking solution. After incubation, the sections were
rinsed in PBS three times. The slides were immersed in
70% ethanol supplemented with 0.1% Sudan Black B
for 15 min and washed 70% ethanol twice to eliminate or
reduceautoﬂuorescenceasdescribedpreviously[15].The
specimens were observed under a confocal microscope.
An independent investigator blind to the treatment of the
samples counted the number of positive cells.
Western blotting
Western blot analysis was performed by a conventional
method as described previously [16]. Phosphorylated
Akt was detected using a phospho-Akt antibody. The
protein expression was detected by ECL® (enhanced
chemiluminescence; GE Healthcare) according to the
manufacturer’s instructions. Membranes were scanned
using LAS-4000mini (Fujiﬁlm). The membranes were
stripped and reprobed with an antibody against Akt
(which recognizes both phosphorylated and non-
phosphorylated forms of Akt) by the same procedure.
The level of phosphorylated Akt was normalized to that
of total Akt. Activation of ERK, JNK and p38 MAPK
was examined by the same method. Physostigmine, an
acetylcholinesterase inhibitor (10 nmol/l), was added to
circumventtheeffectofacetylcholinesteraseintheculture
medium for in vitro study.
ELISA
The serum of the mouse was collected and frozen at
−80◦Cuntilassay.ConcentrationsofIL-1β,IL-6,TNFα
andVEGFweredeterminedbyELISAusingappropriate
commercial kits (R&D Systems). The gastrocnemial
muscle of the ischaemic limb lysed in sample buffer of
Western blot analysis was also subjected to ELISA for
cytokine measurement.
Statistical analysis
Statistical analysis was performed with one-way
ANOVA and Fisher test, if appropriate. Results are
shown as means+ −S.E.M. P<0.05 was considered to be
statistically signiﬁcant.
RESULTS
Inhibition of angiogenesis by
acetylcholinesterase inhibitors
Laser Doppler perfusion imaging revealed a rapid
decrease and gradual recovery of the ischaemic/non-
ischaemic hindlimb perfusion ratio after ligation of
unilateral femoral artery (Figures 1A and 1B). The
blood ﬂow recovery of the hindlimb was signiﬁcantly
attenuated in donepezil-treated mice. Physostigmine,
another acetylcholinesterase inhibitor that is structurally
different from donepezil, also attenuated blood ﬂow
recovery, indicating that activation of cholinergic system
attenuates angiogenesis in the hindlimb. Consistent with
the results of laser Doppler perfusion analysis, treatment
with donepezil or physostigmine signiﬁcantly decreased
the capillary density immunohistochemically evaluated
with an anti-CD31 antibody in the ischaemic hindlimb
(Figures 1C and 1D).
BP and body weight were not signiﬁcantly different
between acetylcholinesterase inhibitor-treated mice and
control mice after 2 weeks of unilateral femoral artery
ligation (see Supplementary Table S2 at http://www.
clinsci.org/cs/123/cs1230241add.htm). Treatment with
donepezil signiﬁcantly reduced HR. However, physo-
stigmineatthedoseweuseddidnotaffectHR,indicating
that HR reduction does not play a major role in the
attenuation of blood ﬂow recovery.
We then determined the effect of the speciﬁc agonist
of mAChR (muscarinic ACh receptor; bethanechol) or
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Figure 1 Acetylcholinesterase inhibitors attenuate neovascularization in a mouse model of hindlimb ischaemia
The effect of donepezil or physostigmine on blood ﬂow recovery after hindlimb ischaemia was examined (A–D). The effect of bethanechol or nicotine on blood ﬂow
recovery after hindlimb ischaemia was examined (E–H). (A, E), Representative laser Doppler perfusion images of blood ﬂow after 2 weeks of hindlimb ischaemia are
shown. (B, F) Ratio of blood ﬂow in the ischaemic hindlimb to that in the non-ischaemic hindlimb measured immediately (day 0) and at the days indicated int h e
Figure after unilateral femoral artery ligation. (C, G) Immunohistochemical staining for CD31 in the gastrocnemial muscle of ischaemic hindlimb is shown. (D, H)
Capillary density expressed as the number of capillaries per HPF (high-power ﬁeld). Results are expressed as means+ −S.E.M. (n=7). ∗P <0.05 compared with the
control group.
nAChR (nicotinic ACh receptor; nicotine) on the blood
ﬂow recovery and capillary density of the ischaemic
hindlimb (Figures 1E–1H). Bethanechol reduced blood
ﬂow recovery and capillary density of the ischaemic
hindlimb, suggesting that mAChR is responsible for
the attenuation of blood ﬂow recovery by cholinergic
stimulation. In contrast, nicotine enhanced blood ﬂow
recovery. Although the mechanism is not clear, the net
effect of acetylcholinesterase inhibitors on angiogenesis
favours mAChR stimulation in our model.
Donepezil suppressed VEGF and IL-1β
expression in the ischaemic hindlimb
mRNA expression of angiogenic factors and cytokines
in the ischaemic hindlimb harvested at day 7 was
examined (Figure 2A). The expression of VEGF mRNA
was signiﬁcantly decreased in the donepezil-treated
mice. However, expression of other angiogenic factors
includingbFGF,PDGF,PLGF(placentalgrowthfactor),
Angpt (angiopoietin) 1 and 2 was not affected by
donepezil treatment. Expression of IL-1β and TNFα
mRNA in the ischaemic hindlimb was signiﬁcantly
decreased in the donepezil-treated group, suggesting
an anti-inﬂammatory effect of donepezil. qRT–PCR
also showed a trend towards reduction of CD3ε
(T-lymphocytes) and F4/80 (macrophages) mRNA in
the ischaemic hindlimb of the donepezil-treated mice
compared with that of control mice. Although the
difference was not statistically signiﬁcant, the results
suggest that treatment with donepezil mildly suppressed
inﬁltration of inﬂammatory cells into the ischaemic
hindlimb.
Protein level of IL-1β was signiﬁcantly suppressed
in an ischaemic hindlimb of donepezil-treated mice
(Figure 2B). Although VEGF level was also decreased
in an ischaemic hindlimb of donepezil-treated mice, the
differenceofVEGFlevelbetweencontrolanddonepezil-
treated mice showed a borderline signiﬁcance. We could
not detect any changes in the serum levels of IL-1β, IL-6,
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Figure 2 mRNA and protein expression in the ischaemic
hindlimb of control and donepezil-treated mice
(A) mRNA expression of angiogenic factors and inﬂammatory cytokines in the
ischaemic hindlimb of control (bar C) and donepezil-treated (bar D) mice was
quantiﬁed with real time RT–PCR. The primer sequences used are indicated in
Supplementary Table S1 at http://www.clinsci.org/cs/123/cs1230241add.htm. The
expression level of each mRNA in the ischaemic hindlimb of control mouse was set
as 100% (n=7). ∗P <0.05 compared with the control group. (B) Protein level
of IL-1β and VEGF in the ischaemic hindlimb of control and donepezil-treated
mice was measured by ELISA (n=4). ∗P <0.05 compared with the control
group.
or VEGF (results not shown). TNFα was not detectable
in the serum and in ischaemic hindlimb in both groups.
These ﬁndings suggest that donepezil locally suppressed
inﬂammation in an ischaemic hindlimb.
IL-1β reversed the anti-angiogenic effect
of donepezil
A previous report showed that recipient-derived IL-1β
plays an important role in blood ﬂow recovery in the
ischaemic hindlimb [10,17]. As IL-1β expression was
decreased in the ischaemic hindlimb of the donepezil-
treated mice, we injected recombinant murine IL-1β into
the ischaemic hindlimb. An injection of IL-1β resto-
red the reduced blood ﬂow recovery (Figures 3A and
3B) and capillary formation (Figures 3C and 3D) in the
donepezil-treated mice. Donepezil-induced suppression
of VEGF mRNA expression in the ischaemic hindlimb
was also reversed by the IL-1β injection (Figure 3E). The
IL-1β injection did not cause haemodynamic changes
(see Supplementary Table S3 at http://www.clinsci.
org/cs/123/cs1230241add.htm).
Role of PI3K (phosphoinositide 3-kinase)
pathway in hypoxia-induced IL-1β
induction
To gain an insight into the mechanism of donepezil
inhibition of IL-1β expression, we used C2C12 cells,
a mouse embryonic myoblast cell line. As hindlimb
muscles are exposed to hypoxic conditions after femoral
artery ligation, the effect of low oxygen concentration
(1% O2) on IL-1β mRNA expression was determined.
After exposure to the hypoxic condition for 12 h, IL-
1β mRNA level was signiﬁcantly increased compared
with that in C2C12 cells incubated in normoxic (20%
O2) conditions (Figure 4A). The induction of IL-1β
by hypoxic conditions was signiﬁcantly inhibited by
pre-incubation with ACh. The Ach-induced suppression
of IL-1β was reversed by the presence of atropine,
a competitive antagonist of mAChR, but not by
mecamylamine, a speciﬁc antagonist of nAChR. These
results indicate that mAChR is responsible for the
suppression of hypoxia-induced IL-1β expression. The
ﬁndings are consistent with the in vivo results that a
mAChR agonist bethanechol inhibited angiogenesis.
It was reported that PI3K and MAPKs are involved in
IL-1β induction [18]. Treatment with LY294002 (PI3K
inhibitor), PD98059 (ERK kinase inhibitor) or SP600125
(JNK inhibitor) signiﬁcantly decreased hypoxia-induced
IL-1β mRNA expression (Figure 4B). ACh attenuated
hypoxia-induced phosphorylation of Akt, a downstream
kinase of PI3K, but did not affect phosphorylation of
ERK, JNK or p38 MAPK in C2C12 cells (Figures 4C–
4F). These results suggest that ACh may suppress
hypoxia-induced IL-1β expression through inhibition
of the PI3K/Akt pathway. Indeed, the phosphorylation
level of Akt but not other MAPKs was decreased
in the ischaemic hindlimb of donepezil-treated mice
(Figures 4G–4J).
DISCUSSION
We have shown in the present study that treatment
with donepezil attenuated blood ﬂow recovery of
the ischaemic hindlimb in mice through reduction of the
expression of IL-1β. It was suggested that mAChR
is involved in this process. ACh as well as PI3K
inhibitor suppressed hypoxia-induced IL-1β induction
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Figure 3 IL-1β reverses donepezil-induced inhibition of neovascularization
(A) Representative laser Doppler perfusion images of blood ﬂow in the ischaemic hindlimb of donepezil-treated mice with or without IL-1β injection are shown.
Control indicates ischaemic hindlimb without donepezil treatment. (B) Ratio of blood ﬂow in the ischaemic hindlimb to that in the non-ischaemic hindlimb. ∗P <0.05
compared with control. (C) Immunohistochemical staining for CD31 in the gastrocnemial muscle of ischaemic hindlimb is shown. (D) Capillary density that is expressed
as the number of capillaries per HPF. (E) mRNA expression of VEGF was quantiﬁed with real-time RT–PCR. Results are expressed as means+ −S.E.M. (n=6–8).
∗P <0.05 compared with control; #P <0.05 compared with donepezil+PBS.
in C2C12 cells. Donepezil suppressed Akt activation
in the ischaemic hindlimb, suggesting that an increase
in Ach level by donepezil may inhibit hypoxia-induced
IL-1β induction through suppression of the PI3K/Akt
pathway, resulting in the inhibition of VEGF induction
and angiogenesis.
A recent meta-analysis by Singh et al. [19] revealed
that inhalation of anti-cholinergics is associated with a
signiﬁcant increase in the risk of cardiovascular events
in patients with COPD (chronic obstructive pulmonary
disease). Inhalation of anti-cholinergics signiﬁcantly
increasedtheriskofmyocardialinfarctionandcardiovas-
cular death without a statistically signiﬁcant effect on the
risk of stroke. This meta-analysis may support the idea
that anti-cholinergics, contrary to acetylcholinesterase
inhibitors, accelerate angiogenesis in the atherosclerotic
plaque and thereby increase its vulnerability, which
results in an increase in the cardiovascular events.
However, a very recent double-blind trial that examined
the effect of tiotropium, one of the anti-cholinergics,
in patients with COPD showed opposite results [20].
Treatment with tiotropium showed an insigniﬁcant
decrease in the number of death in patients with COPD
and signiﬁcantly decreased the incidence of myocardial
infarction compared with placebo. Therefore the issue
regarding the effect of anti-cholinergics treatment on
cardiovascular events is still controversial.
Stimulation of nAChR is reported to enhance prolifer-
ation of endothelial cells and angiogenesis [13], which is
consistent with the present study. Although stimulation
of mAChR by bethanechol suppressed angiogenesis, the
mechanism by which acetylcholinesterase inhibitors that
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Figure 4 Ach and donepezil suppresses Akt activation
(A) C2C12 myoblast cells were pre-incubated with ACh (100 nmol/l) in the
presence of atropine (Atr, 10 μmol/l) or mecamylamine (Mec, 10 μmol/l) prior
to exposure to hypoxia (1% O2) for 1 h. After exposure to hypoxic condition for
12 h, the IL-1β mRNA level was determined with real time RT–PCR. N, normoxia.
(B) The effects of PD98059 (PD; an ERK inhibitor, 10 μmol/l), SB203580 (SB;
a p38 MAPK inhibitor, 10 μmol/l), LY294002 (LY; a PI3K inhibitor, 10 μmol/l)
and SP600125 (SP; a JNK inhibitor, 10 μmol/l) on hypoxia-induced IL-1β mRNA
expression in C2C12 cells were examined. mRNA expression of IL-1β in C2C12 cells
cultured under normoxia (N) is used as control. ∗P <0.05 compared with under
normoxic conditions; #P <0.05 compared with hypoxia; †P <0.05 compared
with hypoxia+Ach (n=4). (C–F) Effect of ACh on hypoxia-induced activation
of Akt and MAPK was examined. (G–J) Effect of donepezil on the activation
of Akt and MAPK in the non-ischaemic (Con) and ischaemic (ISC) hindlimb was
examined. The ratio of phosphorylated form to total protein level of each kinase is
shown in the histograms (n=4). ∗P <0.05 compared with control, #P <0.05
compared with the ischaemic hindlimb without donepezil.
are supposed to stimulate both nAChR and mAChR
mimic the effect of mAChR is not clear.
OurinvitroresultssuggestthattheincreasedAChmay
be targeting ischaemic muscle of hindlimb, because Ach
inhibited hypoxia-induced IL-1β expression in myoblast
cells and donepezil reduced IL-1β expression in the
ischaemic hindlimb. Therefore the anti-inﬂammatory
effect of ACh on regenerating skeletal muscle may
be dominant compared with direct effects of Ach
on endothelial cells. Although we cannot exclude
possible non-speciﬁc effects of these acetylcholinesterase
inhibitors on angiogenesis, this is unlikely because
the structure of donepezil and physostigmine is
quite different.
ThesourceofAChinthishindlimbischaemiamodelis
notclearatthispoint.ItispossiblethatanincreaseinACh
in the motor nerve ending of neuromuscular junction
may play a role. Recent studies suggest that macrophages
express choline acetyltransferase, which produces Ach
from choline and acetyl-CoA [21]. Therefore inﬁltrated
inﬂammatory cells may be another possible source of
ACh. Alternatively, the ischaemic muscle itself may be
the source of ACh, because it was previously reported
that immunoreactivity of choline acetyltransferase is
observed in both myoblasts and myotubes [22]. Another
possibility is that acetylcholinesterase inhibitors may
suppress angiogenesis in an indirect manner. mAChR
in the CNS is reported to be involved in choliner-
gic anti-inﬂammatory pathway. Intracerebroventricular
administration of muscarine, an agonist for mAChR,
inhibitedLPS-inducedproductionofTNFα intheserum
[23]. We cannot exclude the possible effect of these
acetylcholinesterase inhibitors on the CNS in mediating
an anti-angiogenic effect. Further study is needed to
clarify the source and target cells of ACh in the ischaemic
hindlimb.
Arecentreportshowedthatchronichypoxiaincreased
Akt phosphorylation in human macrophages [24].
Another report showed that TNFα-induced IL-1β
expression is dependent on PI3K/Akt and NF-κB
activation[18].WeshowedthatAchsuppressedhypoxia-
induced IL-1β expression and Akt phosphorylation in
C2C12 cells. And PI3K inhibitor suppressed hypoxia-
induced IL-1β expression. Therefore it is suggested
that Ach suppresses hypoxia-induced IL-1β expression
through inhibition of PI3K/Akt pathway. Although
it is known that PTEN (phosphatase and tensin
homologue deleted on chromosome 10) negatively
regulates PI3K/Akt pathway, we could not detect any
change in PTEN expression in the ischaemic hindlimb
in donepezil-treated mice (results not shown). The
mechanism by which Ach inhibition of hypoxia-induced
PI3K/Akt pathway is not clear and further study is
needed.
The limitation of the present study is that the dose of
donepezil used in this study is very high compared with
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that clinically used for treatment of patients with AD.
Therefore we must be cautious whether donepezil at a
clinical dose affects angiogenesis in patients. A dose of 5–
10 mg/kgofbodyweightperdayofdonepezilusedinthis
study is widely used to examine the effect of donepezil
on dementia in a rodent model [12] despite the fact that
the clinical dose is 5–10 mg/day for patients with AD. It
maybepossiblethatdifferentialsusceptibilitytothedrug
between humans and mice account for the requirement
for high dose of donepezil in rodent models. A recent
study showed a very small increase in skin temperature
in the ischaemic hindlimb by donepezil, suggesting an
angiogenic effect of donepezil [25]. The reason for the
discrepancy between the previous study and our study is
not clear at this point. However, the dose of donepezil
administered to mice is higher in this study compared
with the previous study (5 mg/kg of body weight per
day), which may explain the discrepancy. Alternatively,
the discrepancy may be because the previous report
measured skin temperature rather than blood ﬂow. In
addition, the authors failed to examine the time course
and measured surface temperature at later stage (28 days
after ligation of femoral artery). We could not exclude
the possibility that the difference of blood ﬂow recovery
of ischaemic hindlimb between control and donepezil-
treated mice disappears or reverses after day 14 of
femoralarteryligation.However,mostofthestudyusing
C57BL/6 mice showed that blood ﬂow recovery after
hindlimb ischaemia reaches a plateau at day 14 or 21
[26,27]. Therefore this possibility is unlikely. And an
anti-angiogenic effect of acetylcholinesterase inhibitor is
conﬁrmed by physostigmine in our study. Therefore it
is suggested that acetylcholinesterase inhibitor has an
anti-angiogenic effect at least under our experimental
conditions.
In summary, we have shown in the present study
that treatment with donepezil attenuated angiogenesis.
Stimulation of cholinergic system may be a novel anti-
angiogenic therapy.
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Table S1 Sequences of the primers used in real-time PCR
Angpt 1 and 2, angiopoietin 1 and 2; PlGF, placental growth factor.
Sequence (5 →3 )
Gene Forward Reverse
TNFα AAGCCTGTAGCCCACGTCGTA GGCACCACTAGTTGGTTGTCTTTG
IL-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT
IL-6 CCACTTCACAAGTCGGAGGCTTA GCAAGTGCATCATCGTTGTTCATAC
VEGF GCACATAGGAGAGATGAGCTTCC CTCCGCTCTGAACAAGGCT
Angpt1 CCGAGCCTACTCACAGTACGACAG AAATCGGCACCGTGTAAGATCAA
Angpt2 GGACAGTCATCCAACACCGAGA CAAACTCATTGCCCAGCCAGTA
PDGF CAAAGGCAAGCACCGAAAGTTTA CCGAATCAGGCATCGAGACA
bFGF GTGCCAACCGGTACCTTGCTA TCAGTGCCACATACCAACTGGAG
PlGF CCTGTCTGCTGGGAACAACTCA CACCTCATCAGGGTATTCATCCAAG
CD3ε CACTCTGGGCTTGCTGATGG TCATAGTCTGGGTTGGGAACAGG
F4/80 GAGATTGTGGAAGCATCCGAGAC GATGACTGTACCCACATGGCTGA
β-Actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATG
Table S2 HR, BP and body weight in the experimental
groups
Results are means+ −S.E.M. ∗P <0.05 compared with control.
Group HR (beats/min) SBP (mmHg) Body weight (g)
Control 555+ −34 101+ −10 24.8+ −0.8
Donepezil 452+ −31∗ 97+ −6 23.3+ −0.3
Physostigmine 501+ −20 100+ −2 23.2+ −0.7
Nicotine 522+ −56 101+ −17 24.3+ −1.9
Betahnechol 472+ −47 95+ −8 23.8+ −1.9
Received 6 December 2011/26 January 2012; accepted 28 February 2012
Published as Immediate Publication 28 February 2012, doi:10.1042/CS20110633
Table S3 HR, BP and body weight in the experimental
groups treated with donepezil with or without IL-1β
Results are means+ −S.E.M.
Group HR (beats/min) SBP (mmHg) Body weight (g)
Control+PBS 531+ −21 104+ −6 24.1+ −0.5
Donepezil+PBS 490+ −26 100+ −4 23.7+ −1.7
Donepezil+IL-1β 501+ −8 105+ −3 23.6+ −0.6
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